tiprankstipranks
Trending News
More News >
XWELL (XWEL)
NASDAQ:XWEL
Advertisement

XWELL (XWEL) AI Stock Analysis

Compare
978 Followers

Top Page

XWEL

XWELL

(NASDAQ:XWEL)

Rating:48Neutral
Price Target:
$1.00
▼(-10.71% Downside)
XWELL's overall stock score is primarily impacted by its poor financial performance, characterized by negative equity and cash flow issues. While technical indicators show some short-term bullish momentum, the long-term outlook remains bearish. Valuation metrics are weak due to ongoing losses. The recent corporate event of regaining Nasdaq compliance is a positive note, but the underlying financial distress remains a significant concern.

XWELL (XWEL) vs. SPDR S&P 500 ETF (SPY)

XWELL Business Overview & Revenue Model

Company DescriptionXWELL (XWEL) is a wellness-focused company that operates primarily in the health and wellness sector, providing innovative solutions and services designed to enhance the well-being of its customers. The company specializes in health-related products and services, including wellness facilities, health assessments, and personalized health programs aimed at improving physical and mental health outcomes.
How the Company Makes MoneyXWELL generates revenue through multiple streams, including service fees from wellness assessments, memberships for access to health facilities, and sales of health-related products. The company also partners with corporate clients to provide wellness programs for their employees, creating a steady revenue source from corporate contracts. Additionally, XWELL may benefit from retail partnerships and collaborations that enhance its market reach, contributing to its overall earnings.

XWELL Earnings Call Summary

Earnings Call Date:Aug 14, 2025
(Q3-2024)
|
% Change Since: -6.67%|
Next Earnings Date:Nov 12, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in revenue growth, strategic market expansion, and cost reductions, with improved financial metrics compared to the previous year. However, there were challenges such as increased salaries and legal expenses. Overall, the positive aspects and strategic advancements outweigh the negatives.
Q3-2024 Updates
Positive Updates
Revenue Growth
Total revenue for Q3 2024 was approximately $8.4 million, up from $7.5 million in the prior year period.
Strategic Expansion Plans
Planning to expand into several attractive markets in Florida, with up to 10 XWELL properties expected by mid-2025. Opening first Naples Wax location in November 2024.
Successful Cost Reduction
Reduced total operating expenses by approximately 35% for the 9-month period in 2024 compared to the same period in 2023.
Decrease in Operating Loss
Operating loss for Q3 2024 was $4.8 million, a significant improvement from an operating loss of $12.1 million in the prior year third quarter.
Solid Financial Position
No long-term debt with cash and cash equivalents at $4.4 million and $11.7 million in marketable securities.
Positive Customer Engagement
Customer traction and foot traffic at the new Philadelphia International Airport XpresSpa have been solid, with promising performance from tech-forward installations.
Negative Updates
Increased Salaries and Benefits
Salaries and benefits were approximately $1.9 million in Q3 2024, compared to $1.2 million in the same period in 2023.
Legal Expenses Impact
General and administrative expenses were approximately $4.5 million, including over $2 million related to extraordinary legal expenses.
Company Guidance
During the XWELL Q3 2024 earnings call, several key metrics and strategic initiatives were highlighted. Total revenue for the quarter was approximately $8.4 million, a notable increase from $7.5 million in the same period last year. Revenue sources included $4.9 million from XpresSpa and Treat locations, $3.1 million from XpresTest, and $0.4 million from Naples Wax Center. Operating expenses significantly decreased to $6.8 million from $13.2 million in Q3 2023, contributing to a reduced operating loss of $4.8 million compared to $12.1 million the previous year. The company has also made strides in cost management, with a 35% reduction in total operating expenses over the first nine months of 2024 compared to the same period in 2023. XWELL is focusing on expanding its market presence, particularly in Florida, and is set to open new locations, including its first Naples Wax location and a spa at Penn Station. The company maintains a solid liquidity position with $4.4 million in cash and $11.7 million in marketable securities, with no long-term debt.

XWELL Financial Statement Overview

Summary
XWELL is facing significant financial challenges, with deteriorating revenue and profitability metrics. The balance sheet shows weakened financial health with negative equity, and cash flow issues persist, reflecting operational inefficiencies and liquidity concerns. The company is under financial distress, requiring strategic adjustments to improve its financial position.
Income Statement
35
Negative
The company's revenue has decreased significantly over the years, with a notable decline from 2021 to 2023. Gross profit margin improved slightly in 2023 compared to 2022, but remains weak at 26.3%. Net profit margin is negative, indicating consistent losses. EBIT and EBITDA margins are also negative, reflecting operational challenges despite some improvement in EBIT in 2024.
Balance Sheet
30
Negative
The company has a negative stockholders' equity in 2024, indicating financial distress. The debt-to-equity ratio is not meaningful due to negative equity. The equity ratio is also negative, signaling potential solvency issues. Total assets have decreased significantly, impacting the company's financial stability.
Cash Flow
28
Negative
Operating cash flow is negative, indicating cash outflows from operations. Free cash flow is also negative, reflecting ongoing financial strain. Cash flow from financing activities has been inconsistent, with a significant drop in 2024. The operating cash flow to net income ratio suggests poor cash generation relative to net income.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue30.60M33.90M30.11M55.94M73.73M8.38M
Gross Profit6.27M8.92M3.68M12.05M32.43M-3.60M
EBITDA-13.69M-13.99M-15.75M-19.12M7.87M-19.54M
Net Income-19.33M-16.85M-27.74M-32.63M3.35M-92.23M
Balance Sheet
Total Assets22.45M25.35M38.99M70.43M127.27M103.13M
Cash, Cash Equivalents and Short-Term Investments8.15M11.80M23.05M42.19M105.51M89.80M
Total Debt9.98M10.77M11.09M14.11M13.82M15.38M
Total Liabilities18.32M17.61M18.02M22.48M27.33M22.76M
Stockholders Equity-4.77M-788.00K13.00M39.93M92.73M77.81M
Cash Flow
Free Cash Flow-15.90M-12.80M-18.45M-31.02M6.97M-29.36M
Operating Cash Flow-13.44M-11.01M-16.07M-24.19M15.64M-25.01M
Investing Cash Flow7.80M5.89M5.65M-34.84M-6.24M-4.35M
Financing Cash Flow5.00M1.36M8.00K-27.38M6.35M117.22M

XWELL Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.12
Price Trends
50DMA
1.05
Positive
100DMA
0.96
Positive
200DMA
1.13
Negative
Market Momentum
MACD
0.02
Positive
RSI
51.34
Neutral
STOCH
17.84
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XWEL, the sentiment is Positive. The current price of 1.12 is above the 20-day moving average (MA) of 1.12, above the 50-day MA of 1.05, and below the 200-day MA of 1.13, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 51.34 is Neutral, neither overbought nor oversold. The STOCH value of 17.84 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XWEL.

XWELL Risk Analysis

XWELL disclosed 52 risk factors in its most recent earnings report. XWELL reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

XWELL Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
62
Neutral
$13.67M10.0623.48%12.93%66.81%
61
Neutral
$47.16M0.51548.07%-4.88%
49
Neutral
$155.52M41.411.73%-37.62%-87.69%
48
Neutral
$6.22M-1069.01%-6.93%22.70%
46
Neutral
C$217.46M-0.36-24.12%3.15%19.33%-0.50%
41
Neutral
$6.33M-259.91%373.32%98.46%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
XWEL
XWELL
1.12
-0.68
-37.78%
MED
Medifast
14.29
-5.69
-28.48%
RGS
Regis
19.95
-3.11
-13.49%
MRM
MEDIROM Healthcare Technologies
1.77
-0.71
-28.63%
TRNR
Interactive Strength Inc
3.84
-611.46
-99.38%

XWELL Corporate Events

Delistings and Listing ChangesRegulatory Filings and Compliance
XWELL Regains Nasdaq Compliance After Bid Price Recovery
Positive
Aug 7, 2025

On August 7, 2025, XWELL, Inc. announced that it has regained compliance with the Nasdaq Listing Rule 5550(a)(2) after its common shares maintained a closing bid price of at least $1.00 for 16 consecutive business days, from July 16, 2025, to August 6, 2025. This follows a previous notification from Nasdaq on May 13, 2025, regarding the company’s failure to meet the minimum bid price requirement, which has now been resolved.

Shareholder MeetingsBusiness Operations and Strategy
XWELL Amends Bylaws to Alter Voting Requirements
Neutral
Jul 25, 2025

On July 24, 2025, XWELL, Inc. amended its bylaws to change the voting requirements for stockholder decisions. The amendment lowers the required stockholder vote for matters other than director elections to a majority of votes cast, excluding abstentions and broker non-votes, potentially impacting the company’s decision-making process and shareholder influence.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 08, 2025